Palatin Technologies Q1 Net Loss Narrows On Lower Expenses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2025
0mins
Source: NASDAQ.COM
Financial Performance: Palatin Technologies reported a narrower net loss of $4.81 million in Q1, down from $8.44 million a year ago, attributed to lower operating expenses following the sale of Vyleesi's rights to Cosette Pharmaceuticals.
Operational Progress: The company highlighted advancements in its obesity and ocular pipelines, with promising results from Phase 2 and Phase 3 studies, while trading of its stock transitioned from NYSE American to OTC Pink Market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PTN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PTN
Wall Street analysts forecast PTN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTN is 50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 16.950
Low
50.00
Averages
50.00
High
50.00
Current: 16.950
Low
50.00
Averages
50.00
High
50.00
About PTN
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The Company's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The Company's PL9588 is being developed as a topical treatment for glaucoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pattern Computer CEO to Reveal 2026 Top 10 Predictions with 95.3% Accuracy Rate
- Event Announcement: Pattern Computer will host its annual Top 10 Predictions event on January 28, 2026, where CEO Mark R. Anderson will share insights with a 95.3% accuracy rate, aiding global tech leaders and investors in navigating future economic trends.
- Tech-Driven Economy: The event will delve into technology trends driving economic growth, coupled with international and geopolitical dynamics, providing decision-makers with a comprehensive perspective to enhance competitiveness in complex market environments.
- Virtual Salon Interaction: For SNS members unable to attend in person, Pattern will hold a virtual Spark salon on January 29, 2026, to further discuss the predictions, ensuring all members gain access to crucial market insights and trend analyses.
- AI Platform Innovation: Pattern Computer leverages its proprietary PatternDE™ AI platform, employing breakthrough pattern discovery algorithms to reveal hidden relationships in complex data, thereby enhancing transparency and trust across industries and showcasing its leadership in the AI sector.
Continue Reading
Pattern Computer CEO Mark R. Anderson to Speak at Pitchforce Investment Summit on AI in Life Sciences
- Summit Appearance: Pattern Computer's Chair and CEO Mark R. Anderson will speak at the Pitchforce Investment Summit on January 14, 2026, in San Francisco, discussing the significance of AI in life sciences, which is expected to attract considerable investor interest.
- Industry Innovation Drive: The summit brings together innovative startups and active investors in the life sciences sector, aiming to foster capital and strategic connections through curated pitches and networking, thereby driving further industry development.
- AI Application Prospects: The application of AI in life sciences is fundamentally changing how value is created and managed, with Pattern leveraging its proprietary PatternDE™ platform to uncover hidden relationships in complex data, enhancing efficiency in biopharma manufacturing and clinical trial data flow.
- Transparency and Trust: Pattern's new approach eliminates hypothesis bias through data-driven pattern discovery, providing explainable scientific findings that set a new standard for trust and transparency in AI and scientific innovation, addressing the industry's growing demand for data integrity.
Continue Reading